Conditions: Plaque Psoriasis
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 10
Healthy volunteers: no

Brief summary:
A Multi-Center, Open-Label, Phase 2 Clinical Trial to Evaluate the Safety, Tolerability, and Efficacy of ADX-629 Administered Orally to Subjects with Plaque Psoriasis

Detailed description:

Arms:
arm 1: None

Interventions: intervention 1: ADX-629
Intervention descriptions: intervention 1: ADX-629 administered orally twice daily (BID) for approximately 12 weeks.

Protocol document:
Prot_000.pdf: 





































































































































































SAP_001.pdf: